Goldman Sachs
FBRX icon

Goldman Sachs’s Forte Biosciences FBRX Stock Holding History

Goldman Sachs’s Portfolio FBRX Stock Details FBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.38M Sell
53,473
-14,550
-21% -$419K ﹤0.01% 4852
2025
Q4 		$1.85M Buy
+68,023
New +$1.19M ﹤0.01% 4658
2024
Q3 		– Sell
-831
Closed -$11.2K – 5894
2024
Q2 		$11.2K Hold
831
– – ﹤0.01% 5540
2024
Q1 		$14.5K Buy
831
+1
+0.1% +$17 ﹤0.01% 5416
2023
Q4 		$17K Sell
830
-520
-39% -$7.26K ﹤0.01% 5453
2023
Q3 		$22.3K Buy
1,350
+517
+62% +$11.5K ﹤0.01% 5346
2023
Q2 		$21.7K Buy
833
+8
+1% +$208 ﹤0.01% 5539
2023
Q1 		$20.8K Buy
825
+12
+1% +$302 ﹤0.01% 5664
2022
Q4 		$20.3K Sell
813
-2
-0.2% -$51 ﹤0.01% 5699
2022
Q3 		$22K Sell
815
-497
-38% -$15.8K ﹤0.01% 5917
2022
Q2 		$43K Buy
1,312
+207
+19% +$6.58K ﹤0.01% 6057
2022
Q1 		$40K Sell
1,105
-2,305
-68% -$87.2K ﹤0.01% 6305
2021
Q4 		$182K Buy
3,410
+2,889
+555% +$194K ﹤0.01% 5941
2021
Q3 		$39K Sell
521
-995
-66% -$551K ﹤0.01% 6092
2021
Q2 		$1.27M Buy
1,516
+193
+15% +$174K ﹤0.01% 4583
2021
Q1 		$1.13M Buy
+1,323
New +$1.08M ﹤0.01% 4505
2020
Q1 		– Sell
-131
Closed -$26K – 5306
2019
Q4 		$26K Buy
131
+69
+111% +$15.6K ﹤0.01% 5162
2019
Q3 		$15K Buy
62
+32
+107% +$48.6K ﹤0.01% 5116
2019
Q2 		$74K Sell
30
-126
-81% -$374K ﹤0.01% 4976
2019
Q1 		$636K Buy
156
+30
+24% +$116K ﹤0.01% 4299
2018
Q4 		$387K Buy
126
+65
+107% +$280K ﹤0.01% 4508
2018
Q3 		$356K Sell
61
-6
-9% -$22.8K ﹤0.01% 4610
2018
Q2 		$235K Buy
67
+32
+91% +$117K ﹤0.01% 4918
2018
Q1 		$157K Buy
35
+3
+9% +$13.9K ﹤0.01% 5118
2017
Q4 		$122K Buy
+32
New +$128K ﹤0.01% 5669
2017
Q3 		– Sell
-81
Closed -$366K – 6710
2017
Q2 		$366K Buy
+81
New +$456K ﹤0.01% 5340

Other funds holding FBRX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return

Goldman Sachs's FBRX Position: Q1 2026 in Review

Goldman Sachs reduced its Forte Biosciences (FBRX) stake by 21% in Q1 2026, selling an estimated $419K and leaving 53,473 shares worth $1.38M. The position accounts for ﹤0.01% of the portfolio, ranked #4852.

Goldman Sachs first reported a position in FBRX in Q2 2017 and has held it in 26 quarters since. The position peaked at $1.85M in Q4 2025. 68 funds tracked by Wall St. Rank hold FBRX as of Q1 2026.

  • Goldman Sachs held 53,473 shares of Forte Biosciences worth $1.38M as of Q1 2026.
  • Goldman Sachs sold 14,550 Forte Biosciences shares in Q1 2026, an estimated $419K.
  • Forte Biosciences made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #4852 holding.
  • Goldman Sachs first reported a position in Forte Biosciences in Q2 2017 and has held it in 26 quarters since.
  • Goldman Sachs's Forte Biosciences position peaked at $1.85M in Q4 2025.
  • 68 funds tracked by Wall St. Rank held Forte Biosciences as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.